What is Endostim?
Endostim operates at the intersection of medical device engineering and gastroenterology. The company is dedicated to solving the clinical challenges associated with GERD, a condition that impacts the quality of life for millions of patients worldwide. Its core technology, the EndoStim System, utilizes neurostimulation to restore the function of the lower esophageal sphincter, effectively managing reflux symptoms at the source. While the system remains in the investigational phase within the United States, the company's strategic focus on clinical evidence and regulatory compliance positions it as a significant player in the evolving landscape of neuromodulation and digestive health technology.
How much funding has Endostim raised?
Endostim has raised a total of $94.6M across 12 funding rounds:
Private Equity
$5.5M
Private Equity
$14.1M
Series C
$9.1M
Unspecified
$11.2M
Private Equity
$6.4M
Private Equity
$2.5M
Series D
$25M
Private Equity
$12.1M
Private Equity (2011): $5.5M, investors not publicly disclosed
Private Equity (2012): $14.1M, investors not publicly disclosed
Series C (2013): $9.1M led by Prolog Ventures and Billiken Angels Network
Unspecified (2013): $11.2M, investors not publicly disclosed
Private Equity (2014): $6.4M, investors not publicly disclosed
Private Equity (2015): $2.5M, investors not publicly disclosed
Series D (2016): $25M with participation from Wellington Partners, Sante Ventures, Gimv, and Endeavour Vision
Private Equity (2017): $12.1M, investors not publicly disclosed
Key Investors in Endostim
Sante Ventures
A privately held investment firm managing over $1 billion, focusing on innovative healthcare and technology companies within the Biotech, Medtech, and Healthtech sectors.
Wellington Partners
A leading European venture capital firm specializing in early- and growth-stage life science companies, including medical devices and digital health.
Endeavour Vision
An investment advisory firm focused on transformative healthcare technologies, providing strategic support for clinical trials and regulatory submissions in the medical device space.
What's next for Endostim?
Looking ahead, Endostim is poised to leverage its recent capital influx to accelerate its clinical development programs and navigate the complex regulatory pathways required for broader market adoption. The strategic backing from specialized healthcare investors provides the necessary runway to transition from investigational status to commercial viability. As the company continues to gather longitudinal data on the efficacy of its neurostimulation system, the focus will likely shift toward scaling manufacturing capabilities and establishing robust commercialization strategies in key international markets. By maintaining its focus on high-unmet-need patient populations, Endostim remains well-positioned to disrupt the standard of care for chronic reflux management.
See full Endostim company page
